Delving into the Latest Updates on IGT-303 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

IGT 303, IGT303

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Ingenia Therapeutics Inc.

Active Organization

Ingenia Therapeutics Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is:
Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)).
Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use.
Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.

Start Date30 Oct 2025

Sponsor / Collaborator

Ingenia Therapeutics Inc.

100 Clinical Results associated with IGT-303

Login to view more data

100 Translational Medicine associated with IGT-303

Login to view more data

100 Patents (Medical) associated with IGT-303

Login to view more data

100 Deals associated with IGT-303

Login to view more data